Nov. 18, 2026—Quest Diagnostics has launched its FDA-authorized AAVrh74 antibody ELISA companion diagnostic through Sarepta Therapeutics’ sponsored testing program for people with Duchenne muscular dystrophy. The enzyme-linked immunosorbent assay is intended for the semiquantitative detection of IgG antibodies to AAVrh74 capsid in human serum. It is used to help identify patients with Duchenne who may be eligible for Sarepta’s gene therapy.
The test reports an antibody titer and a semiquantitative interpretation derived from that titer. Patients with an AAVrh74 antibody titer less than 1:400 are reported as not elevated for AAVrh74 antibody titers and may be eligible for treatment with the gene therapy. A titer greater than or equal to 1:400 is reported as elevated, and these patients are ineligible for treatment with the gene therapy. The test is for prescription use only and intended to be used with other available clinical information.